Ignite Creation Date:
2024-05-06 @ 3:01 AM
Last Modification Date:
2024-10-26 @ 11:27 AM
Study NCT ID:
NCT02186821
Status:
TERMINATED
Last Update Posted:
2021-04-08
First Post:
2014-07-03
Brief Title:
Ceritinib LDK378 for Patients Whose Tumors Have Aberrations in ALK or ROS1 SIGNATURE
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis